VEC-162
Description
Name: VEC-162
Type: small molecule
Groups: investigational
Indication: Investigated for use/treatment in insomnia and sleep disorders.
Accession Number: DB05359 ( DB05359)
Description: VEC-162 is a melatonin agonist under development for the treatment of sleep disorders (insomnia, circadian rhythm sleep disorders) and mood disorders (including depression). Vanda licensed VEC-162 from Bristol-Myers Squibb Company in 2004. Vanda has completed phase II for VEC-162 in insomnia and has initiated a phase III trial.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: investigational
Indication: Investigated for use/treatment in insomnia and sleep disorders.
Accession Number: DB05359 ( DB05359)
Description: VEC-162 is a melatonin agonist under development for the treatment of sleep disorders (insomnia, circadian rhythm sleep disorders) and mood disorders (including depression). Vanda licensed VEC-162 from Bristol-Myers Squibb Company in 2004. Vanda has completed phase II for VEC-162 in insomnia and has initiated a phase III trial.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|
| Brand Name | Ingredients |
|---|
Categories
- No Category
Pharmacology
Indication: Investigated for use/treatment in insomnia and sleep disorders.
Pharmacodynamics: Not Available
Mechanism of action: VEC-162 is a balanced melatonin (MT1/MT2) receptor agonist developed by Vanda Pharmaceuticals Inc. It has demonstrated improvements in objective and subjective measures of sleep onset and maintenance in a Phase III trial of transient insomnia.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: VEC-162 is a balanced melatonin (MT1/MT2) receptor agonist developed by Vanda Pharmaceuticals Inc. It has demonstrated improvements in objective and subjective measures of sleep onset and maintenance in a Phase III trial of transient insomnia.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Not Available
Packagers:
- Not Available
Dosage forms
| Form | Route | Strength |
|---|
| Form | Route | Strength |
|---|
Prices
| Unit description | Cost | Unit |
|---|
| Unit description | Cost | Unit |
|---|
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|
| Drug | Interaction |
|---|
Food Interactions:
- Not Available
Taxonomy
Kingdom: Not Available
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
Synthesis Reference: Not Available
General Reference: Not Available
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: Not Available
External Links:
| Resource | Link |
|---|
| Resource | Link |
|---|
ATC Codes:
- Not Available
AHFS Codes:
- Not Available
MSDS: Download